For patients, the immediate impact is a reduction in the final cost of therapies that often run into lakhs per month.
Procter & Gamble has announced Shailesh Jejurikar as its next CEO, effective January 1, 2026. Jejurikar, an India-born executive, will succeed Jon Moeller in the role.
The $1.2 billion in-space manufacturing market is expected to grow and be worth more than $20 billion by 2033.
India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact.
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
Barring a few, such as Andhra Pradesh Chief Minister N Chandrababu Naidu (74), Union Minister C R Patil (69) and Uttar Pradesh Finance Minister Suresh Khanna (71), most other ministers attending the WEF represent the next generation of India's politicians.
The Indian arm of Swiss pharmaceutical major Novartis AG is set to become the newest entrant in the Ayurvedic business.
Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
The multinational has filed infringement proceedings and is seeking an injunction against the Indian rival at the Delhi High Court, trying to block the Bangalore-based biotechnology firm from launching a generic version of Galvus, also known as vildagliptin.
In a development that could hasten the entry of the generic version of Gleevec into the US market, Indian drug major Sun Pharma has sued Novartis Pharmaceuticals Corp in the District Court of New Jersey, demanding rights to launch a generic version of the cancer drug before the Novartis patent expires.
Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?
Novartis disputes the claims and will defend itself, spokeswoman Julie Masow said in an email.
Novartis' threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover.
Data contradict Swiss drug major's claim that India does not respect IPR.
The Supreme Court had rejected the company's plea for a patent on cancer drug Glivec in April.
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad
The company is likely to increase buy-back offer from Rs 351 to Rs 425-450. The open offer price is likely to be revised from the earlier Rs 351 to between Rs 425 and Rs 450, as the current share prices of Novartis India are above the present open offer price, the sources added.
Drug major Novartis has been slapped with a Rs 300-crore penalty by drug regulator NPPA for overcharging consumers on sale of Voveran, its best-selling painkiller medicine.
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
The patent department made this declaration on August 16 after Novartis had failed to respond to its queries within the prescribed time.
On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.
The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.
Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.
Novartis markets Nilotinib globally as Tasigna, which is used as the second-line therapy for Gleevec-resistant patients in the case of chronic myelogenous leukemia.
Swiss drug major Novartis' Indian arm is upbeat about its rural sales initiative, Arogya Parviar and plans to double its reach in the country over the next few years. "Arogya Parivar that started as a novel rural marketing initiative is now a profit-making body.
The denial of patent to Glivec was the first case of a multinational being denied patent protection for a drug that enjoys monopoly marketing rights in about 40 countries.
Novartis plunged a solid 13.29% to Rs 229 on turning out an unsavoury 93% drop in net profit for the quarter ended 31 March 2003.\n\n\n\n
The drug Glivec was a genuinely new and important discovery deserving of patent protection.
Brian Druker, who invented the drug's molecule, says it would benefit patients in the short term.
The international health organisations, protesting against Swiss pharmaceutical major Novartis AG's legal challenge to provisions of the Indian Patent Act
Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically.
The company will continue to introduce products in the country, but not invest in R&D here, Novartis India Ltd Vice-Chairman and Managing Director Ranjit Shahani said at a press conference in Mumbai.
It plans to make Hyderabad as its back office hub for data management in clinical research and financial service segments. Novartis is putting infrastructure to put all these people in one place and the centre is expected to turn operational next year. It will be the back office for Novartis' pharmaceutical operations and will find many PhDs and post-graduates working there, said Jurgen Brokatzky-Geiger, head (human resources), Novartis.
Terming the judgement as a 'landmark judgement' in favour of poor patients, domestic drug manufacturer associations, including Indian Pharmaceutical Alliance and Indian Drug Manufacturers' Association, hailed the apex court's decision.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances